Core Viewpoint - Jianyou Co., Ltd. announced that it will not adjust the conversion price of its convertible bonds despite triggering the downward adjustment clause due to stock prices falling below 90% of the conversion price for 15 out of 30 trading days [2] Group 1 - As of December 12, 2025, Jianyou Co., Ltd. has experienced a situation where the closing price of its stock has been below 90% of the current conversion price for 15 trading days [2] - The company's board of directors decided not to proceed with a downward adjustment of the conversion price at this time [2] - The company has set a future period of four months, from December 13, 2025, to April 12, 2026, during which it will also not propose a downward adjustment if the clause is triggered again [2]

| 股票代码：603707 | 股票简称：健友股份 | 公告编号：2025-091 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于不向下修正"健友转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、可转债基本情况 的《南京健友生化制药股份有限公司关于"健友转债"转股价格调整的公告》（公 告编号：2020-061）。 2、公司于2020年7月23日起因实施2019年年度利润分配方案，"健友转债"的 转股价格由54.96元/股调整为42.05元/股。具体内容详见公司2020年7月17日披露的 《南京健友生化制药股份有限公司关于"健友转债"转股价格调整的提示性公告》 （公告编号：2020-070）。 3、公司于2021年6月25日起因实施2021年限制性股票激励计划，"健友转债" 的转股价格由42.05元/股调整为42.01元/股。具体内容详见公司2021年6月24日披露 的《南京健友生化制药股份有 ...

| 股票代码：603707 | 股票简称：健友股份 | 公告编号：2025-091 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于不向下修正"健友转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、可转债基本情况 经中国证券监督管理委员会"证监许可［2020］603号"文核准，南京健友生 化制药股份有限公司于2020年4月23日公开发行了5,031,900张可转换公司债券（以 下简称"可转债"），每张面值100元，发行总额50,319.00万元，期限为6年。 经上海证券交易所自律监管决定书［2020］134号文同意，公司50,319.00万元 可转换公司债券于2020年5月22日起在上海证券交易所挂牌交易，债券简称"健友 转债"，债券代码"113579"。 根据《上海证券交易所股票上市规则》等相关规定及《南京健友生化制药股份 有限公司公开发行可转换公司债券募集说明书》（以下简称"《募集说明书》 ...

Group 1 - The company, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., issued 5,031,900 convertible bonds with a total amount of RMB 503.19 million, which are set to mature on April 22, 2026 [1] - The initial conversion price of the convertible bonds was set at RMB 54.97 per share, which has been adjusted multiple times due to various corporate actions, with the latest adjustment bringing it down to RMB 24.54 per share as of July 7, 2023 [2] - The company’s board has the authority to propose a downward adjustment of the conversion price if the stock price falls below 90% of the current conversion price for at least 15 out of 30 consecutive trading days [3] Group 2 - The company decided not to adjust the conversion price of the convertible bonds during the upcoming six months, even if the conditions for adjustment are met [4] - If the stock price continues to fall and triggers the adjustment conditions after November 24, 2025, the board will reconvene to decide on the potential adjustment [5]

健友股份（603707.SH）12月5日在投资者互动平台表示，门冬胰岛素已经提交申请，若获批公司会第 一时间发布公告。赖脯胰岛素预计在2027年提交申请，甘精胰岛素预计在2026年提交申请，前述期限均 为预估期限，请您关注公司后续发布的公告，以公告内容为准。 每经AI快讯，有投资者在投资者互动平台提问：请问公司与通化东宝合作的三款胰岛素（甘精胰岛 素、门冬胰岛素、赖脯胰岛素）产品，是否已经提交FDA审批，预计获批时间？能对该三款产品在美国 销售预期做展望吗？ （记者 王晓波） ...

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-090 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于"健友转债"预计满足 转股价格修正条款的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、可转债的发行上市概况 经中国证券监督管理委员会《关于核准南京健友生化制药股份有限公司公开 发行可转换公司债券的批复》（证监许可[2020]603 号）核准，南京健友生化制 药股份有限公司（以下简称"公司"）公开发行了 5,031,900 张可转换公司债券 （以下简称"可转债"或"健友转债"），每张面值人民币 100 元，发行总额人 民币 5.0319 亿元，本次可转债存续期限为发行之日起六年，即自 2020 年 4 月 23 日至 2026 年 4 月 22 日。 经上海证券交易所自律监管决定书[2020]134 号文同意，公司 5.0319 亿元 可转债于 2020 年 5 月 22 日起在上海证券 ...

（记者 曾健辉） 每经AI快讯，有投资者在投资者互动平台提问：公司研制的格拉替雷是否已提交FDA审批预计何时上 市销售？ 健友股份（603707.SH）12月5日在投资者互动平台表示，尊敬的投资者您好，格拉替雷已经提交FDA 审批，后续进展请您关注公司发布的公告，谢谢。 ...

Core Viewpoint - The company is nearing the completion of the Phase II clinical trial for the XTMAB project, with further announcements expected soon [1] Summary by Categories - **Clinical Trial Progress** - The Phase II clinical trial for the XTMAB project is approaching its conclusion [1]

Core Points - The company, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., has received ANDA approval from the U.S. FDA for its Propofol Emulsion Injection in three specifications: 200 mg/20 mL, 500 mg/50 mL, and 1,000 mg/100 mL [1][2][3] - The reference formulation for Propofol Emulsion Injection is held by Fresenius Kabi USA LLC, which was approved by the U.S. FDA in June 1996 under the brand name DIPRIVAN [2] - Currently, there are eight other manufacturers in the U.S. that have approved generic versions of Propofol Emulsion Injection [2] - The company has invested approximately RMB 73.66 million in the research and development of the Propofol Emulsion Injection project [2] - The newly approved product is expected to be launched in the U.S. soon, which is anticipated to have a positive impact on the company's operating performance [2] Drug Information - Drug Name: Propofol Emulsion Injection [3] - Indication: General anesthesia and sedation [3] - Dosage Form: Injection [3] - Specifications: 200 mg/20 mL, 500 mg/50 mL, 1,000 mg/100 mL [3] - ANDA Number: 217945 [3] - Applicant: Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. [3]

Group 1 - Guizhou BaiLing's actual controller Jiang Wei has been investigated by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations [1] - The investigation highlights the regulatory focus on key individuals and may increase operational uncertainty for Guizhou BaiLing, which has faced performance pressures in recent years [1] - The CSRC's actions reflect ongoing efforts to enhance the rule of law in the capital market [1] Group 2 - Jianyou Co., Ltd. has received ANDA approval from the FDA for its Propofol emulsion injection, marking a significant step in the company's internationalization of its formulations [2] - The product is expected to have a broad market potential in the U.S. as a commonly used sedative for surgeries, potentially driving revenue growth for the company [2] Group 3 - Shenzhen Xinlitai has been granted clinical trial approval for its innovative small molecule drug SAL0140, aimed at treating chronic kidney disease (CKD) [3] - SAL0140 is a proprietary aldosterone synthase inhibitor with potential applications in multiple significant chronic disease areas, indicating substantial market potential [3] - Successful development could open new growth avenues for Shenzhen Xinlitai [3] Group 4 - Junshi Biosciences reported a decrease in the shareholding percentage of Greenland Financial Investment Group and its affiliates from 5.0051% to 4.7129% due to share lending [4] - This change is a technical operation rather than an active reduction in holdings, but it brings the shareholding below the 5% disclosure threshold, warranting market attention on future actions [4] Group 5 - Sichuan Sichuang Medical Technology Co., Ltd. announced the resignation of Chairman Xu Yiran to facilitate governance structure optimization, while he will remain a board member [5] - The appointment of Wei Naixu as the new chairman indicates a strategic move to clarify responsibilities and strengthen governance rather than a response to a crisis [5]